Anna Kwiatkowska Selected Research

Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)

1/2019	Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.
12/2018	Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue.
1/2018	Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.
12/2017	PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
8/2017	PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.
8/2017	Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations.
1/2017	Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3.
2/2015	PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.
1/2015	Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.
5/2014	Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anna Kwiatkowska Research Topics

Disease

13	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 12/2012
10	Neoplasms (Cancer) 03/2022 - 01/2014
2	COVID-19 03/2022 - 03/2021
2	Human Influenza (Influenza) 03/2021 - 01/2014
2	Communicable Diseases (Infectious Diseases) 03/2021 - 04/2015
2	Schizophrenia (Dementia Praecox) 01/2014 - 07/2013
1	Atherosclerosis 03/2022
1	Virus Diseases (Viral Diseases) 03/2021
1	Influenza in Birds (Avian Flu) 03/2021
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 04/2019
1	Hemorrhagic Disorders (Hemorrhagic Diathesis) 04/2019
1	Breast Neoplasms (Breast Cancer) 08/2017
1	Adenocarcinoma 08/2017
1	Ovarian Neoplasms (Ovarian Cancer) 05/2014
1	Neoplasm Metastasis (Metastasis) 05/2014
1	Ascites 05/2014
1	Infections 01/2014

Drug/Important Bio-Agent (IBA)

10	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 01/2019 - 05/2014
8	FurinIBA 03/2022 - 12/2012
6	Peptides (Polypeptides)IBA 03/2021 - 12/2012
4	EnzymesIBA 03/2021 - 01/2014
2	Hemagglutinins (Hemagglutinin)IBA 03/2021 - 01/2014
2	Serine Proteases (Serine Protease)IBA 01/2018 - 01/2017
2	PeptidomimeticsIBA 02/2015 - 01/2014
1	SARS-CoV-2 spike proteinIBA 03/2022
1	Inosine Triphosphate (ITP)IBA 04/2019
1	AlbuminsIBA 01/2019
1	ProdrugsIBA 01/2019
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2019
1	Serine (L-Serine)FDA Link 12/2018
1	Enzyme Precursors (Zymogens)IBA 12/2017
1	Protein Isoforms (Isoforms)IBA 12/2017
1	AndrogensIBA 12/2017
1	Biomarkers (Surrogate Marker)IBA 08/2017
1	Estrogen ReceptorsIBA 08/2017
1	3-Mercaptopropionic Acid (3 Mercaptopropionic Acid)IBA 08/2017
1	peptide AIBA 01/2015
1	Antineoplastic Agents (Antineoplastics)IBA 05/2014
1	Small Interfering RNA (siRNA)IBA 05/2014
1	tetrapeptide carbamateIBA 05/2014
1	Proteins (Proteins, Gene)FDA Link 05/2014
1	Shiga Toxin (Shigella Toxin)IBA 01/2014
1	AcidsIBA 01/2014
1	Superoxides (Superoxide)IBA 01/2014
1	AntioxidantsIBA 01/2014
1	Thrombin FDA Link 01/2014
1	Platelet Activating FactorIBA 01/2014
1	Glutathione PeroxidaseIBA 01/2014
1	AnionsIBA 01/2014
1	Antipsychotic Agents (Antipsychotics)IBA 07/2013

Therapy/Procedure

1	Splenectomy 04/2019
1	Platelet Transfusion (Blood Platelet Transfusions) 04/2019
1	Therapeutics 01/2014